Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Rheumatology Priorities Advanced at Busy AMA House of Delegates Meeting

From the College  |  June 16, 2023

Two ACR-led resolutions on in-office specialty drug dispensing and the proposed NIH Public Access Plan passed the House of Delegates and will become AMA policy.

Filed under:Legislation & Advocacy Tagged with:ACR advocacyAMA House of Delegates (HOD)National Institutes of Health (NIH)research publishing

Methotrexate Shortage: Why It’s Happening & Potential Solutions

Michele B. Kaufman, PharmD, BCGP  |  May 31, 2023

In recent months, many rheumatologists and rheumatology professionals have noted issues related to obtaining supplies of injectable and oral methotrexate for their patients with rheumatoid arthritis (RA). A conventional synthetic disease-modifying anti-rheumatic drug (csDMARD), methotrexate is available as both oral tablets and as a subcutaneous injection for the treatment of RA and other autoimmune diseases.1…

Filed under:Drug Updates Tagged with:Drug shortagedrug treatmentMethotrexatepatient careRheumatoid Arthritis (RA)

Case Report: Migratory Polyarthritis as the Presenting Symptom of GPA

Adil Vural, MD, & Kinanah Yaseen, MD  |  May 9, 2023

Granulomatosis with polyangiitis (GPA) is a primary, necrotizing granulomatous vasculitis, involving small- to medium-sized arteries, that causes systemic disease. Almost any organ can be affected, but the most affected systems are the upper airways, lungs, kidneys, eyes and peripheral nerves. Migratory polyarthritis is reported in approximately 25% of patients with anti-neutrophil cytoplasmic antibody (ANCA) associated…

Filed under:ConditionsVasculitis Tagged with:AAV FocusRheumANCA-Associated Vasculitiscase reportGranulomatosisgranulomatosis with polyangiitismigratory polyarthritis

Insights from a Neuro-Rheumatology Clinic

Kristin Galetta, MD, Shamik Bhattacharyya, MD, & Simon M. Helfgott, MD  |  April 7, 2023

Neuro-rheumatology is a fast-growing field. Better testing and imaging have increased recognition of once-infrequent diagnoses, such as neuro-sarcoidosis and amyloid beta-related angiitis. Concurrently, the rapid expansion of immunotherapy options to treat cancer and their untoward neurological side effects have increased the frequency of referrals to both neurologists and rheumatologists. Identifying and treating neurologic manifestations of…

Filed under:Practice Support Tagged with:collaborationCollaboration Initiativesinterdisciplinaryneuro-rheumatologyNeurology

Cardiovascular Safety with RA Treatments

Michele B. Kaufman, PharmD, BCGP  |  March 2, 2023

Research by Chicre et al. found that Janus kinase inhibitors may significantly increase the risk of major adverse cardiac events and all-cause death in patients with rheumatoid arthritis (RA) when compared with other RA treatments. This study highlights the need for more comparative safety studies.

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:cardiovascularcardiovascular eventJAK inhibitorJanus Kinase InhibitorsRA Resource CenterRheumatoid Arthritis (RA)TNF inhibitorsTofacitinib

Supplemental Vitamin D May Not Protect Against Fractures in Healthy Adults

Lara C. Pullen, PhD  |  March 2, 2023

Supplemental vitamin D may not significantly lower the risk of fractures in generally healthy adults compared with placebo, according to a large study by LeBoff et al.

Filed under:Conditions Tagged with:fracture riskFracturesVitamin Dvitamin D supplementationVitamin D3

Top 10 Tricks for the Management of Dry Mouth

Samantha C. Shapiro, MD  |  February 15, 2023

PHILADELPHIA—Whether due to Sjögren’s disease or something else, dry mouth is a common chief complaint from patients with rheumatic illnesses. Dry mouth isn’t life-threatening, but it can have a serious impact on quality of life. Sialogogues like cevimeline and pilocarpine may benefit some, but not all, patients, but cholinergic side effects often limit their usefulness….

Filed under:ACR ConvergenceConditionsSjögren’s Disease Tagged with:ACR Convergence 2022Sjogren's

Healthcare Policy Prospects in the 118th Congress

From the College  |  February 4, 2023

The U.S. government remains divided. Democrats hold the White House and the Senate by one vote, and Republicans lead the House. Amid this division, the ACR is watching possible areas to advance healthcare legislation. Meet the committees and members with the largest jurisdiction over healthcare policy.

Filed under:Legislation & Advocacy Tagged with:ACR advocacyhealthcare lawpolicy issuesU.S. Congress

A World of Difference: Updates from the Global Rheumatology Summit

Jason Liebowitz, MD, FACR  |  January 20, 2023

The second annual Global Rheumatology Summit focused on climate change, conflict and migration, as well as other global issues in rheumatology.

Filed under:ACR ConvergenceConditionsMeeting ReportsMyositis Tagged with:ACR Convergence 2022Global Rheumatology Summitidiopathic inflammatory myositisMentorshippatient accessWorkforce

Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw

Michele B. Kaufman, PharmD, BCGP  |  December 12, 2022

A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesEULARONJosteonecrosis of the jawOsteoporosiszoledronic acid

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 83
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences